CSIMarket
 


Elite Pharmaceuticals Inc   (ELTP)
Other Ticker:  
 

Cumulative Elite Pharmaceuticals Inc 's Total Debt to Equity for Trailing Twelve Months Period

ELTP's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

ELTP Total Debt to Equity for Trailing Twelve Months Period

(Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Equity Growth 53.82 % 65.84 % 17.95 % 14.82 % 32.41 %
Y / Y Total Debt Growth -82.48 % -82.34 % -78.33 % 444.27 % 2386.08 %
Total Debt to Equity for Trailing Twelve Months Period 0.07 0.17 0.3 0.4 0.39
Total Ranking # 461 # 551 # 579 # 691 # 846
Seq. Equity Growth 2.93 % 49.73 % 3.99 % -4.02 % 10.97 %
Seq. Total Debt Growth -1.29 % -2.03 % -1.7 % -81.57 % -0.52 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to repayements of liabilities of -1.29% Elite Pharmaceuticals Inc decreased Total Debt to Equity for Trailing Twelve Months Period in the III. Quarter to 0.07, below company's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 76 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Elite Pharmaceuticals Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
ELTP Charts and Quotes
Total Debt to Equity ELTP in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 77
Sector # 167
S&P 500 # 606


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
2.53 0.35 0.03
(Dec 31 2019)   (Mar 31 2022)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Sanofi  0.19 
Equillium Inc   0.19 
Provention Bio Inc   0.19 
Iveric Bio Inc   0.19 
Intercure Ltd   0.19 
Qualigen Therapeutics Inc   0.19 
Mereo Biopharma Group Plc  0.18 
Cue Biopharma Inc   0.18 
Imunon Inc   0.16 
Frequency Therapeutics Inc   0.16 
Inozyme Pharma Inc   0.16 
Roivant Sciences Ltd   0.16 
Kamada Ltd   0.15 
Beigene ltd   0.15 
Actinium Pharmaceuticals Inc   0.15 
Opko Health Inc   0.15 
Elite Pharmaceuticals Inc   0.15 
Kazia Therapeutics Limited  0.15 
Biodexa Pharmaceuticals Plc  0.15 
United Therapeutics Corporation  0.14 
Adial Pharmaceuticals Inc   0.14 
Vaxxinity Inc   0.14 
Universe Pharmaceuticals Inc  0.14 
180 Life Sciences Corp  0.14 
Talphera Inc   0.13 
Longeveron Inc   0.13 
Vaccinex Inc   0.12 
Regulus Therapeutics Inc   0.12 
Aldeyra Therapeutics Inc   0.12 
Palatin Technologies Inc   0.11 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com